Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6183

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
11 July 2023 In progress. Scoping commenced. Please note that the evaluation of selpercatinib for untreated RET-positive advanced thyroid cancer ID6183, will now be conducted via ID6132 selpercatinib for untreated advanced thyroid cancer with RET alterations.
25 October 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual